{"protocolSection": {"identificationModule": {"nctId": "NCT00904488", "orgStudyIdInfo": {"id": "08-1292"}, "organization": {"fullName": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "briefTitle": "Oral Metolazone and Intermittent Intravenous Furosemide Versus Continuous Infusion Furosemide in Acute Heart Failure", "officialTitle": "Addition of Oral Metolazone to Intermittent Intravenous Furosemide Versus Transition to Continuous Infusion Furosemide in Acute Decompensated Heart Failure Patients Experiencing an Inadequate Response to Therapy"}, "statusModule": {"statusVerifiedDate": "2018-01", "overallStatus": "TERMINATED", "whyStopped": "Difficult recruitment", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2016-05-28", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-11-14", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-05-17", "studyFirstSubmitQcDate": "2009-05-18", "studyFirstPostDateStruct": {"date": "2009-05-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-12-08", "resultsFirstSubmitQcDate": "2018-01-17", "resultsFirstPostDateStruct": {"date": "2018-02-13", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-02-13", "lastUpdatePostDateStruct": {"date": "2018-03-13", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of North Carolina, Chapel Hill", "class": "OTHER"}, "collaborators": [{"name": "University of Illinois at Chicago", "class": "OTHER"}, {"name": "Virginia Commonwealth University", "class": "OTHER"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this prospective, randomized, open-label study is to compare two diuretic strategies in patients with acute decompensated heart failure (ADHF): the addition of an oral thiazide diuretic to intravenous bolus (IVB) loop diuretic will be compared to transition from IVB to continuous infusion (CI) loop diuretic.", "detailedDescription": "Patients hospitalized for ADHF secondary to fluid overload and who are experiencing an inadequate response to IVB furosemide and require additional diuresis will be enrolled. Patients will be randomized to one of two treatment arms: the addition of oral metolazone to continued IVB furosemide versus transition from IVB to CI furosemide. A suggested algorithm for initial dosing and titration of these two diuretic strategies will be provided. Baseline and daily data collection will include various efficacy and safety endpoints including daily net urine output and weight, patient and physician global assessment scale, length of stay, 30-day death or rehospitalization, vital signs, electrolytes, and renal function. Clinically meaningful efficacy and safety endpoints will be compared."}, "conditionsModule": {"conditions": ["Acute Decompensated Heart Failure"], "keywords": ["Acute Decompensated Heart Failure", "Diuretics"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 11, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Addition of PO Thiazide Diuretic", "type": "ACTIVE_COMPARATOR", "description": "Addition of oral metolazone 5 mg daily to current intravenous bolus furosemide. All subjects will continue their current dose of intravenous bolus furosemide.", "interventionNames": ["Drug: Addition of oral Metolazone"]}, {"label": "IV furosemide dose escalation", "type": "ACTIVE_COMPARATOR", "description": "Current IV furosemide dose will be escalated to 2-2.5 x current dose, given as either IV bolus or continuous infusion over 24 hours.", "interventionNames": ["Drug: Furosemide dose escalation"]}], "interventions": [{"type": "DRUG", "name": "Addition of oral Metolazone", "description": "Addition of oral metolazone 5 mg daily to continued current dose of intravenous bolus furosemide", "armGroupLabels": ["Addition of PO Thiazide Diuretic"], "otherNames": ["Zaroxolyn"]}, {"type": "DRUG", "name": "Furosemide dose escalation", "description": "Furosemide dose escalation via either IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)", "armGroupLabels": ["IV furosemide dose escalation"], "otherNames": ["Lasix"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization)", "description": "Net fluid output = fluid output during 24-48 hours after randomization - fluid intake during 24-48 hours after randomization. A negative value means that daily fluid intake was less than the daily fluid output.", "timeFrame": "24-48 hours"}], "secondaryOutcomes": [{"measure": "Daily Net Fluid Output on Days 1, 3, and 4", "description": "Daily net fluid output = daily fluid output - daily intake. A negative value means that daily fluid intake was less than the daily fluid output.", "timeFrame": "0-24, 48-72, 72-96 hrs"}, {"measure": "Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)", "timeFrame": "0-24, 24-48, 48-72, 72-96 hrs"}, {"measure": "Daily Weight", "timeFrame": "Baseline (Dry), Baseline, 0-24, 24-48, 48-72, 72-96 hrs"}, {"measure": "Patient Global Assessment Scale", "description": "Scale range: 1-5 Which of the following best describes your overall health state today?\n\n1. = markedly worse\n2. = worse\n3. = neither better nor worse\n4. = better\n5. = markedly better", "timeFrame": "Baseline, 24, 48, 72, 96 hrs"}, {"measure": "Physician Global Assessment Scale", "description": "Scale range: 1-5 Which of the following best describes the patient's overall health state today?\n\n1. = markedly worse\n2. = worse\n3. = neither better nor worse\n4. = better\n5. = markedly better", "timeFrame": "Baseline, 24, 48, 72, 96 hours"}, {"measure": "Need for Additional or Alternative Diuretic (Crossover) or Other Vasoactive Therapy (Study Failure)", "description": "Patients will be considered a treatment failure if they require additional diuretic (including crossover to the alternative study arm) or require IV vasoactive drug therapy (e.g. vasodilators including nitroglycerin or inotropes) as deemed appropriate/necessary by their medical team.", "timeFrame": "0-96 hours"}, {"measure": "Time to Return to Baseline Weight", "timeFrame": "0-96 hours"}, {"measure": "Length of Hospitalization", "timeFrame": "Assessed till hospital discharge, an average of 1 week (longest 29 days)"}, {"measure": "30-day All-cause Mortality", "timeFrame": "30 days"}, {"measure": "Rehospitalization at 30 Days", "timeFrame": "30 days"}, {"measure": "Unscheduled Heart Failure Visits to Emergency Department or Outpatient Clinic", "timeFrame": "30 days"}, {"measure": "Blood Urea Nitrogen (BUN)", "timeFrame": "Baseline, 24, 48, 72, 96 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Greater than or equal to 18 years of age\n2. Hospitalized for acute decompensated heart failure (ADHF) secondary to fluid overload as defined by the presence of at least\n\n   * 1 symptom (e.g. dyspnea, orthopnea, paroxysmal nocturnal dyspnea) AND\n   * 1 sign (e.g. rales on auscultation, \\> 2+ peripheral or presacral\\> edema, hepatomegaly, ascites, jugular vein distension \\> 7 cm, pulmonary vascular congestion on chest radiography)\n3. Inadequate response to IV diuretics and requiring additional diuresis as determined by primary medical team\n4. Received less than six doses of IV furosemide OR enrolled within 72 hours of hospital admission\n5. Anticipated need for intravenous diuretic therapy for at least 48 hours\n6. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Receiving a continuous infusion loop diuretic during current hospital visit\n2. Substantial diuretic response to pre-randomization diuretic dosing such that higher doses of diuretic would be contraindicated (based on judgement of patient's primary team)\n3. Planned or ongoing intravenous vasoactive therapy (e.g. inotrope, vasodilator) or mechanical support (e.g. intra-aortic balloon pump, ventricular assist device) for ADHF during this hospitalization\n4. Planned elective admission for elective placement/revision of a cardiovascular device (e.g. defibrillator, biventricular pacemaker) during this hospitalization or such within the preceding 7 days\n5. Systolic blood pressure \\< 90 mmHg\n6. Serum creatinine \\> 3 mg/dL at baseline or renal replacement therapy including ultrafiltration\n7. Serum potassium \\< 3.5 mEq/L (3.0 - 3.4 mEq/L allowed if supplemental potassium is being administered)\n8. Serum magnesium \\< 1.6 mg/dL (1.4 - 1.5 mg/dL allowed if supplemental magnesium is being administered)\n9. Acute coronary syndrome or hemodynamically significant arrhythmias causing worsening HF\n10. Severe, uncorrected primary cardiac valvular disease, acute myocarditis, constrictive pericarditis, hypertrophic obstructive cardiomyopathy, restrictive or constrictive cardiomyopathy, complex congenital heart disease\n11. Primary pulmonary hypertension with right sided heart failure\n12. Use of iodinated radiocontrast material in prior 72 hours or planned within the next 48 hours\n13. Enrollment or planned enrollment in another randomized clinical trial during hospitalization", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Jo E. Rodgers, PharmD", "affiliation": "University of North Carolina, Chapel Hill", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "UNC_Chapel Hill", "city": "Chapel Hill", "state": "North Carolina", "zip": "27599", "country": "United States", "geoPoint": {"lat": 35.9132, "lon": -79.05584}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Furosemide Dose Escalation", "description": "Furosemide dose escalation given either as IV bolus (2-2.5 x current dose) or continuous infusion (2-2.5 x current dose administered over previous 24 hours)"}, {"id": "FG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "BG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "57.6", "spread": "16.0"}, {"groupId": "BG001", "value": "55.8", "spread": "16.2"}, {"groupId": "BG002", "value": "56.6", "spread": "15.3"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}]}]}, {"title": "Baseline Ejection Fraction (EF) (%)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"title": "Mild (55-60%)", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Moderate (20-40%)", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "6"}]}, {"title": "Severe (5-15%)", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Chief Complaints", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Shortness of Breath (SOB)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Weight Gain", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Fluid Overload", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Afib on Admission", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"title": "Present", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Absent", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Not reported", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}]}, {"title": "New York Heart Association (NYHA) Class on Admission", "description": "ClassI No limitation of physical activity. Best outcome.\n\nClassII Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea (shortness of breath).\n\nClassIII Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.\n\nClassIV Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases. Worst outcome", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"title": "Class I", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Class II", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Class III", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "3"}]}, {"title": "Class IV", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Not Reported", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "6"}]}]}]}, {"title": "Comorbidities", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Anemia", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Coronary artery disease (CAD)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}]}, {"title": "Chronic obstructive pulmonary disease (COPD)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Cerebrovascular accident (CVA)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Diabetes", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "Dyslipidemia", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "6"}]}]}, {"title": "Gastroesophageal reflux disease (GERD)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Gout", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Human immunodeficiency virus (HIV)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Myocardial infarction (MI)", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Hypertension", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "Obesity", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Obstructive Sleep Apnea", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Medication", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Beta Blocker", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "8"}]}]}, {"title": "Angiotensin-converting-enzyme inhibitor", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "10"}]}]}, {"title": "Angiotensin Receptor Blockers", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}, {"title": "Loop Diuretic", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Aldosterone Antagonist", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Digoxin", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Calcium Channel Blocker", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Isosorbide Dinitrate", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Hydralazine", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Statin", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Anticoagulant", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "5"}]}]}, {"title": "Aspirin", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "7"}]}]}, {"title": "Potassium supplement", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}]}]}]}, {"title": "Brain Natriuretic Peptide (BNP) at admission", "populationDescription": "BNP was not measured on admission as part of routine clinical care in all subjects.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "pg/ml", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "6800.75", "spread": "10330.95"}, {"groupId": "BG001", "value": "5401.33", "spread": "4183.06"}, {"groupId": "BG002", "value": "6201.00", "spread": "7313.54"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Daily Net Fluid Output on Day 2 (24-48 Hours After Randomization)", "description": "Net fluid output = fluid output during 24-48 hours after randomization - fluid intake during 24-48 hours after randomization. A negative value means that daily fluid intake was less than the daily fluid output.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/day", "timeFrame": "24-48 hours", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1454.60", "spread": "1339.53"}, {"groupId": "OG001", "value": "-1322.83", "spread": "1738.30"}]}]}]}, {"type": "SECONDARY", "title": "Daily Net Fluid Output on Days 1, 3, and 4", "description": "Daily net fluid output = daily fluid output - daily intake. A negative value means that daily fluid intake was less than the daily fluid output.", "populationDescription": "If diuretic therapy is changed to the oral route before a scheduled efficacy endpoint is to be measured (e.g.72 or 96 hour net output), then that endpoint will not be obtained.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml/day", "timeFrame": "0-24, 48-72, 72-96 hrs", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "0-24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2226.74", "spread": "2063.63"}, {"groupId": "OG001", "value": "-3076.67", "spread": "1555.63"}]}]}, {"title": "48-72 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2108.00", "spread": "2187.05"}, {"groupId": "OG001", "value": "-409.74", "spread": "1208.98"}]}]}, {"title": "72-96 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2433.33", "spread": "1374.38"}, {"groupId": "OG001", "value": "-705.33", "spread": "157.39"}]}]}]}, {"type": "SECONDARY", "title": "Daily Urine Output (mL Urine Out Per mg Furosemide (IV Equivalent) Received)", "populationDescription": "Data were not collected at all time points for all subjects, and were only analyzed when available. Data not analyzed on days when diuretics were held or discontinued.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml/mg furosemide received", "timeFrame": "0-24, 24-48, 48-72, 72-96 hrs", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "0-24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "29.35", "spread": "21.01"}, {"groupId": "OG001", "value": "17.35", "spread": "7.11"}]}]}, {"title": "24-48 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.28", "spread": "4.59"}, {"groupId": "OG001", "value": "21.88", "spread": "14.39"}]}]}, {"title": "48-72 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25.84", "spread": "20.05"}, {"groupId": "OG001", "value": "25.52", "spread": "14.84"}]}]}, {"title": "72-96 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "43.94", "spread": "28.12"}]}]}]}, {"type": "SECONDARY", "title": "Daily Weight", "populationDescription": "Data were not collected for all subjects at all time points, and were only analyzed when available", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Kg", "timeFrame": "Baseline (Dry), Baseline, 0-24, 24-48, 48-72, 72-96 hrs", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "Baseline (Dry)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "82.35", "spread": "40.87"}, {"groupId": "OG001", "value": "100.82", "spread": "49.35"}]}]}, {"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "120.84", "spread": "75.25"}, {"groupId": "OG001", "value": "102.57", "spread": "33.57"}]}]}, {"title": "0-24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "154.23", "spread": "103.30"}, {"groupId": "OG001", "value": "101.07", "spread": "32.88"}]}]}, {"title": "24-48 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "129.73", "spread": "91.46"}, {"groupId": "OG001", "value": "99.08", "spread": "32.93"}]}]}, {"title": "48-72 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "135.07", "spread": "101.31"}, {"groupId": "OG001", "value": "106.70", "spread": "52.18"}]}]}, {"title": "72-96 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "172.10", "spread": "107.71"}, {"groupId": "OG001", "value": "86.87", "spread": "48.17"}]}]}]}, {"type": "SECONDARY", "title": "Patient Global Assessment Scale", "description": "Scale range: 1-5 Which of the following best describes your overall health state today?\n\n1. = markedly worse\n2. = worse\n3. = neither better nor worse\n4. = better\n5. = markedly better", "populationDescription": "Data were not collected at all time points, and were only analyzed when available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 24, 48, 72, 96 hrs", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.25", "spread": "1.67"}, {"groupId": "OG001", "value": "3.67", "spread": "2.23"}]}]}, {"title": "24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.2", "spread": "0.45"}, {"groupId": "OG001", "value": "4.25", "spread": "2.23"}]}]}, {"title": "48 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.8", "spread": "1.1"}, {"groupId": "OG001", "value": "3.6", "spread": "1.67"}]}]}, {"title": "72 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.67", "spread": "2.59"}, {"groupId": "OG001", "value": "3.75", "spread": "1.97"}]}]}, {"title": "96 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4", "spread": "2.19"}, {"groupId": "OG001", "value": "4", "spread": "2.19"}]}]}]}, {"type": "SECONDARY", "title": "Physician Global Assessment Scale", "description": "Scale range: 1-5 Which of the following best describes the patient's overall health state today?\n\n1. = markedly worse\n2. = worse\n3. = neither better nor worse\n4. = better\n5. = markedly better", "populationDescription": "Data were not collected at all time points, and were only analyzed when available.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Baseline, 24, 48, 72, 96 hours", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.67", "spread": "1.67"}, {"groupId": "OG001", "value": "2", "spread": "1.21"}]}]}, {"title": "24 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.25", "spread": "1.95"}, {"groupId": "OG001", "value": "4", "spread": "2.16"}]}]}, {"title": "48 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4", "spread": "1.92"}, {"groupId": "OG001", "value": "4", "spread": "1.63"}]}]}, {"title": "72 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.5", "spread": "2.49"}, {"groupId": "OG001", "value": "3.75", "spread": "1.97"}]}]}, {"title": "96 hr", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "4"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4", "spread": "2.19"}, {"groupId": "OG001", "value": "3.67", "spread": "2.19"}]}]}]}, {"type": "SECONDARY", "title": "Need for Additional or Alternative Diuretic (Crossover) or Other Vasoactive Therapy (Study Failure)", "description": "Patients will be considered a treatment failure if they require additional diuretic (including crossover to the alternative study arm) or require IV vasoactive drug therapy (e.g. vasodilators including nitroglycerin or inotropes) as deemed appropriate/necessary by their medical team.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "0-96 hours", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}]}]}]}, {"type": "SECONDARY", "title": "Time to Return to Baseline Weight", "populationDescription": "Weight was not collected in all subjects every day.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "0-96 hours", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.5", "spread": "1.1"}, {"groupId": "OG001", "value": "1.5", "spread": "0.84"}]}]}]}, {"type": "SECONDARY", "title": "Length of Hospitalization", "populationDescription": "Data not available in all subjects.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Days", "timeFrame": "Assessed till hospital discharge, an average of 1 week (longest 29 days)", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.75", "spread": "1.71"}, {"groupId": "OG001", "value": "11.25", "spread": "10.93"}]}]}]}, {"type": "SECONDARY", "title": "30-day All-cause Mortality", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Rehospitalization at 30 Days", "populationDescription": "30-day follow up data (except for mortality) were not collected in 2 participants", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Unscheduled Heart Failure Visits to Emergency Department or Outpatient Clinic", "populationDescription": "30-day follow up data (except for mortality) were not collected in 2 participants", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Blood Urea Nitrogen (BUN)", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, 24, 48, 72, 96 hours", "groups": [{"id": "OG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)"}, {"id": "OG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "6"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "31.20", "spread": "11.05"}, {"groupId": "OG001", "value": "29.83", "spread": "16.82"}]}]}, {"title": "24 hr", "categories": [{"measurements": [{"groupId": "OG000", "value": "28.00", "spread": "9.35"}, {"groupId": "OG001", "value": "27.67", "spread": "17.18"}]}]}, {"title": "48 hr", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.80", "spread": "11.45"}, {"groupId": "OG001", "value": "33.17", "spread": "16.92"}]}]}, {"title": "72 hr", "categories": [{"measurements": [{"groupId": "OG000", "value": "29.00", "spread": "12.08"}, {"groupId": "OG001", "value": "42.00", "spread": "20.70"}]}]}, {"title": "96 hr", "categories": [{"measurements": [{"groupId": "OG000", "value": "38.60", "spread": "19.63"}, {"groupId": "OG001", "value": "42.67", "spread": "20.63"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Changes in labs and vitals were collected for 96 hours after randomization All-cause mortality were collected for 30 days after randomization", "description": "* Total number of times antihypertensive doses are held due to low blood pressure\n* Number of hypotensive episodes defined as systolic blood pressure below 85 mmHg or greater than 10 mmHg below baseline (whichever is greater)\n* Number of critically low potassium (\\< 3.5 mmol/L) and magnesium (\\< 1.6 mg/dL) concentrations while receiving study therapy", "eventGroups": [{"id": "EG000", "title": "Furosemide Dose Escalation", "description": "IV furosemide dose escalation via either intravenous bolus (2-2.5 x current dose) or continuous infusion furosemide (Furosemide 2-2.5 x current dose administered over previous 24 hours)", "deathsNumAffected": 0, "deathsNumAtRisk": 5, "seriousNumAffected": 0, "seriousNumAtRisk": 5, "otherNumAffected": 2, "otherNumAtRisk": 5}, {"id": "EG001", "title": "IVB Loop and PO Thiazide Diuretic", "description": "Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide (Furosemide continued at current dose)", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 6, "otherNumAtRisk": 6}], "otherEvents": [{"term": "critically low potassium (< 3.5 mmol/L) while receiving study therapy", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "critically low magnesium (< 1.6 mg/dL) while receiving study therapy", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Hypotension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 2, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 32, "numAffected": 6, "numAtRisk": 6}]}, {"term": "Hypotension resulting in holding antihypertensive doses", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Reported as number of subjects affected/total at risk. Count of occurrence is total number of doses of antihypertensives being held.", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 5}, {"groupId": "EG001", "numEvents": 8, "numAffected": 1, "numAtRisk": 6}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Jo Ellen Rodgers", "organization": "UNC Eshelman School of Pharmacy", "email": "jerodgers@unc.edu", "phone": "(919) 962-2249"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008788", "term": "Metolazone"}, {"id": "D000005665", "term": "Furosemide"}], "ancestors": [{"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049994", "term": "Sodium Potassium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}], "browseLeaves": [{"id": "M8784", "name": "Furosemide", "asFound": "Myocardial Infarction", "relevance": "HIGH"}, {"id": "M11761", "name": "Metolazone", "asFound": "Narcolepsy", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26153", "name": "Sodium Potassium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}]}}, "hasResults": true}